Premium
Madrigal Pharmaceuticals Inc (YDO1)
TG
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. David SoergelExec. VP & Chief Medical Officer | -1,04k | 516,56k | Automatic Disposition | 495,74 | 10,03k | -9,41% |
| 2026-05-22 | Dr. Richard S. LevyIndependent Director | -5,68k | 2,93M | Automatic Disposition | 506,68 - 519,98 | 21,30k | -21,06% |
| 2026-05-18 | Dr. David SoergelExec. VP & Chief Medical Officer | -844,00 | 435,42k | Vente | 515,90 | 11,08k | -7,08% |
| 2026-03-06 | Ms. Mardi C. DierExec. VP & CFO | -646,00 | 279,03k | Vente | 431,94 | 0,00 | -100,00% |
| 2026-03-06 | Ms. Mardi C. DierExec. VP & CFO | -1,34k | 574,96k | Automatic Disposition | 425,08 - 437,65 | 0,00 | -100,00% |
| 2026-03-06 | Mr. William J. SiboldCEO, President & Director | -1,66k | 718,32k | Vente | 431,94 | 105,91k | -1,55% |
| 2026-03-06 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -360,00 | 155,50k | Vente | 431,94 | 1,82k | -16,51% |
| 2026-03-06 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -419,00 | 180,98k | Vente | 431,94 | 427,00 | -49,53% |
| 2026-03-06 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -491,00 | 212,08k | Vente | 431,94 | 441,03k | -0,11% |
| 2026-03-02 | Ms. Mardi C. DierExec. VP & CFO | -1,18k | 505,39k | Vente | 427,21 | 1,04k | -53,31% |
| 2026-02-23 | Dr. Richard S. LevyIndependent Director | 2,50k | 18,40k | Derivative Exercise and Retained Stock | 7,36 | 26,98k | 10,21% |
| 2026-01-26 | Dr. Richard S. LevyIndependent Director | 4,00k | 65,84k | Derivative Exercise and Retained Stock | 16,46 | 24,48k | 19,53% |
| 2026-01-26 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -340,00 | 167,42k | Vente | 492,42 | 9,12k | -3,59% |
| 2026-01-26 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -570,00 | 281,92k | Automatic Disposition | 494,59 | 9,12k | -5,88% |
| 2026-01-26 | Mr. William J. SiboldCEO, President & Director | -1,58k | 776,55k | Vente | 492,42 | 104,31k | -1,49% |
| 2026-01-26 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -647,00 | 318,60k | Vente | 492,42 | 440,43k | -0,15% |
| 2026-01-20 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -263,00 | 129,07k | Vente | 490,77 | 1,38k | -15,98% |
| 2026-01-20 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -429,00 | 215,10k | Automatic Disposition | 501,40 | 1,38k | -23,68% |
| 2026-01-20 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -2,24k | 1,10M | Vente | 490,77 | 439,63k | -0,51% |
| 2026-01-09 | Dr. Paul A. FriedmanDirector | -24,80k | 12,57M | Derivative Exercise and Sale | 15,80 - 551,24 | 954,00k | - |
| 2026-01-09 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -18,65k | 9,45M | Derivative Exercise and Sale | 15,80 - 551,24 | 436,87k | - |
| 2025-12-10 | Dr. Paul A. FriedmanDirector | -24,80k | 13,30M | Derivative Exercise and Sale | 15,80 - 555,39 | 954,00k | - |
| 2025-12-10 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -18,65k | 10,00M | Derivative Exercise and Sale | 15,80 - 555,39 | 1,11M | - |
| 2025-12-10 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -5,46k | 0,00 | Other Disposition | - | 1,11M | -0,49% |
| 2025-12-03 | Mr. William J. SiboldCEO, President & Director | 47,60k | 0,00 | Derivative Exercise and Retained Stock | - | 102,82k | 86,20% |
| 2025-12-03 | Mr. William J. SiboldCEO, President & Director | -2,40k | 1,38M | Derivative Exercise and Sale | 575,34 | 102,82k | - |
| 2025-12-02 | Ms. Mardi C. DierExec. VP & CFO | -4,17k | 1,36M | Derivative Exercise and Sale | 251,63 - 596,19 | 0,00 | - |
| 2025-11-21 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -1,96k | 1,08M | Vente | 547,27 - 564,57 | 0,00 | -100,00% |
| 2025-11-13 | Dr. Richard S. LevyIndependent Director | -8,50k | 4,31M | Derivative Exercise and Sale | 7,36 - 530,21 | 20,48k | - |
| 2025-11-05 | Mr. Kenneth M. BateInitié | -16,58k | 4,63M | Derivative Exercise and Sale | 9,45 - 490,98 | 1,91k | - |
| 2025-09-09 | Mr. William J. SiboldCEO, President & Director | -7,28k | 3,24M | Vente | 445,63 | 55,22k | -11,65% |
| 2025-08-21 | Mr. William J. SiboldCEO, President & Director | -7,62k | 3,05M | Automatic Disposition | 400,03 - 401,00 | 50,00k | -13,22% |
| 2025-08-18 | Baker Bros. Advisors LPSociété | 151,71k | 56,70M | Achat | 353,88 - 392,24 | 1,94M | 8,46% |
| 2025-08-18 | 667, L.P.Société | 13,98k | 5,22M | Achat | 353,88 - 392,24 | 198,99k | 7,55% |
| 2025-08-18 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -458,00 | 164,27k | Vente | 358,66 | 0,00 | -100,00% |
| 2025-08-18 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -846,00 | 315,36k | Automatic Disposition | 369,64 - 376,62 | 0,00 | -100,00% |
| 2025-08-15 | Mr. Kenneth M. BateInitié | -10,00k | 3,49M | Derivative Exercise and Sale | 16,46 - 368,56 | 1,91k | - |
| 2025-08-11 | Dr. Paul A. FriedmanDirector | -175,98k | 62,79M | Derivative Exercise and Sale | 9,45 - 374,38 | 954,00k | - |
| 2025-08-11 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -46,46k | 16,07M | Derivative Exercise and Sale | 9,45 - 359,71 | 1,12M | - |
| 2025-07-18 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -1 000,00 | 340,56k | Derivative Exercise and Sale | 9,45 - 350,01 | 1,12M | - |
| 2025-07-18 | Dr. Paul A. FriedmanDirector | -1,40k | 476,81k | Derivative Exercise and Sale | 9,45 - 350,03 | 954,00k | - |
| 2025-07-16 | Dr. Paul A. FriedmanDirector | -28,88k | 9,93M | Derivative Exercise and Sale | 9,45 - 356,62 | 954,00k | - |
| 2025-07-16 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -29,10k | 10,00M | Derivative Exercise and Sale | 9,45 - 356,52 | 1,12M | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
